Chronic lymphocytic leukemia (CLL) is the most diagnosed leukemia in the Western world
accounting for approximately 25% of all new leukemia diagnoses. In recent years remarkable
progress has been made in our understanding of both the pathophysiology and genetics of CLL.
While the disease generally affects older adults and initially follows an indolent course
cytogenetic and molecular profiling have helped to predict clinical outcomes. Greater
prognostication alongside the development of an increasing armamentarium of novel targeted
therapies has enabled us to provide more personalized management options for patients.
